State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 401–500 of 1,003
Griffith, D. C., Sabet, M., Tarazi, Z., Lomovskaya, O., & Dudley, M. N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01659-18 · Cited by 89
Which fluoroquinolones are suitable for the treatment of urinary tract infections?
Naber, K. G. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00362-9 · Cited by 89
Gatti, M., Cojutti, P. G., Pascale, R., Tonetti, T., Laici, C., Dell’Olio, A., Siniscalchi, A., Giannella, M., Viale, P., & Pea, F. (2021) · Antibiotics · doi:10.3390/antibiotics10111311 · Cited by 88
“According to experimental animal models, the minimum threshold needed to achieve bactericidal activity with beta-lactams is 40–70% fT>MIC [5], namely, a target that has been adopted in pivotal trials of novel antimicrobial agents [6,7].”
BackgroundAndes, D. R., Craig, W. A., Nielsen, L. A., & Kristensen, H. H. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-08 · Cited by 88
Self-citationDesigning development programs for non-traditional antibacterial agents
Rex, J. H., Lynch, H. F., Cohen, I. G., Darrow, J. J., & Outterson, K. (2019) · Nature Communications · doi:10.1038/s41467-019-11303-9 · Cited by 88
Appropriate antimicrobial treatment in nosocomial infections—the clinical challenges
Masterton, R. G., Drusano, G. L., Paterson, D. L., & Park, G. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00294-9 · Cited by 88
Medicinal and Aromatic Plants - Australia
Cock, I. E. (2011) · Griffith Research Online · Cited by 87
PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
Ahmad, Z., Peloquin, C. A., Singh, R. P., Derendorf, H., Tyagi, S. K., Ginsberg, A. M., Grosset, J. H. E., & Nuermberger, E. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00849-10 · Cited by 87
“Animal models facilitate PD studies because drug exposures may incorporate a large range of drug exposures which are not suitable for clinical use (3).”
BackgroundBeyond conventional antibiotics — New directions for combination products to combat biofilm
Bayramov, D. F., & Neff, J. A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.010 · Cited by 87
“time that it needs to be maintained in vivo in order to design an appropriate antimicrobial drug release mode [59,63].”
BackgroundPerry, T. R., & Schentag, J. J. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140090-00004 · Cited by 87
Patel, B. M., Paratz, J. D., See, N. C., Müller, M. J., Rudd, M., Paterson, D. L., Briscoe, S., Ungerer, J. P. J., McWhinney, B. C., Lipman, J., et al. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31824981a6 · Cited by 86
Antimicrobial treatment challenges in the era of carbapenem resistance
Peri, A. M., Doi, Y., Potoski, B. A., Harris, P. N. A., Paterson, D. L., & Righi, E. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.01.020 · Cited by 86
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin
Kays, M. B., Overholser, B. R., Mueller, B. A., Moe, S. M., & Sowinski, K. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.08.027 · Cited by 86
Pharmacodynamics of Telithromycin In Vitro against Respiratory Tract Pathogens
Odenholt, I., Löwdin, E., & Cars, O. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.23-29.2001 · Cited by 86
Zander, J., Maier, B., Suhr, A., Zoller, M., Frey, L., Teupser, D., & Vogeser, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0746 · Cited by 85
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients
Al‐Shaer, M. H., Rubido, E., Cherabuddi, K., Venugopalan, V., Klinker, K. P., & Peloquin, C. A. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa359 · Cited by 85
Therapeutic drug monitoring for tomorrow
Eliasson, E., Lindh, J. D., Malmström, R. E., Beck, O., & Dahl, M. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1504-x · Cited by 85
“To be more precise, it appears that the free concentration of the beta-lactam should exceed the bacterial MIC by at least half the dose interval [29].”
BackgroundGrayson, M. L., McDonald, M., Gibson, K., Athan, E., Munckhof, W., Paull, P., & Chambers, F. (2002) · Clinical Infectious Diseases · doi:10.1086/340056 · Cited by 85
Telavancin: in vitro activity against staphylococci in a biofilm model
Gander, S., Kinnaird, A., & Finch, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki198 · Cited by 85
Roberts, J. A., Joynt, G. M., Choi, G. Y. S., Gomersall, C. D., & Lipman, J. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.002 · Cited by 85
Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy
Hoffman, A., & Stepensky, D. (1999) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v16.i6.20 · Cited by 85
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
Rayner, C. R., Smith, P. F., Andes, D. R., Andrews, K. A., Derendorf, H., Friberg, L. E., Hanna, D. L., Lepak, A. J., Mills, E. J., Polasek, T. M., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2198 · Cited by 84
“43 A large number of different doses and dosing intervals are administered to infected animals, such as mice with thigh infections.”
Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal
Garot, D., Respaud, R., Lanotte, P., Simon, N., Mercier, E., Ehrmann, S., Perrotin, D., Dequin, P., & Guellec, C. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04005.x · Cited by 84
Jamal, J., Mueller, B. A., Choi, G. Y. S., Lipman, J., & Roberts, J. A. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.01.013 · Cited by 84
Pharmacodynamics of tobramycin in patients with cystic fibrosis
Mouton, J. W., Jacobs, N., Tiddens, H. A. W. M., & Horrevorts, A. M. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.02.011 · Cited by 84
“During the last decade, quantitative relationships between pharmacodynamic indices (PI), such as the area under the concentration–time curve (AUC) divided by the MIC (AUC/MIC ratio) and the time N MIC (T NMIC), and efficacy have been described for antimicrobial drugs (Leggett et al., 1989, 1990; Craig, 1998).”
BackgroundDrug-resistant Streptococcus pneumoniae: rational antibiotic choices
Jacobs, M. R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00351-9 · Cited by 84
Fish, D. N., Teitelbaum, I., & Abraham, E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2421-2428.2005 · Cited by 84
“Studies indicate that T MIC for carbapenems should be at least 40 to 50% of the dosing interval for maximum killing effects and reliable clinical efficacy (3, 4, 6, 39).”
BackgroundQuinolone Activity Against Anaerobes
Appelbaum, P. C. (1999) · Drugs · doi:10.2165/00003495-199958002-00012 · Cited by 84
Inhibition of Nanobacteria by Antimicrobial Drugs as Measured by a Modified Microdilution Method
Çíftçíoglu, N., Miller-Hjelle, M. A., Hjelle, J. T., & Kajander, E. O. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2077-2086.2002 · Cited by 84
Dagan, R., Leibovitz, E., Leiberman, A., & Yagupsky, P. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200005001-00009 · Cited by 84
Kim, A., Sutherland, C. A., Kuti, J. L., & Nicolau, D. P. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.11.1490 · Cited by 83
“Although b-lactams are considered time dependent, they do not require free drug concentrations that remain above the MIC for 100% of the time.(20) Penicillins, like piperacillintazobactam, achieve maximal bactericidal activity at an fT>MIC of 50% or greater, which makes prolonged infusion as advantageous as continuous…”
BackgroundMazzei, T., Cassetta, M. I., Fallani, S., Arrigucci, S., & Novelli, A. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.05.019 · Cited by 83
“Modern pharmacology is going through a period of critical review of the rules for selecting antibiotics and their ideal dosage regimen for the control of infections, with the goals of increasing treatment efficacy and reducing the risk of selecting multiresistant pathogens [4–7].”
BackgroundInfluentialGarrigós, C., Murillo, Ó., Euba, G., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., & Ariza, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00226-10 · Cited by 83
“On the basis of previously reported data, for all drugs we selected the dose at which the area under the concentration-time curve from 0 to 24 h (AUC0–24) values in TCF and serum in animals were close to those in human serum (5, 32).”
Udy, A. A., Roberts, J. A., Lipman, J., & Blot, S. I. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.019 · Cited by 83
“ems) are the most frequently prescribed time-dependent agents [57, 58], with animal studies suggesting that the time above MIC (fTNMIC) – e.”
BackgroundThalhammer, F., & rl, W. H. H. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039040-00003 · Cited by 83
Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles
Zhou, W., Xie, S., Zhu, L., Dong, Z., Wang, Y., & Wang, X. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17083 · Cited by 83
Kawaguchi, N., Katsube, T., ECHOLS, R. M., & Wajima, T. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01437-20 · Cited by 82
Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations
Debbia, E. A., Maioli, E., Roveta, S., & Marchese, A. (2008) · Journal of Chemotherapy · doi:10.1179/joc.2008.20.2.186 · Cited by 82
Microbiology and Principles of Antimicrobial Therapy for Head and Neck Infections
Brook, I. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.03.014 · Cited by 82
Kim, A., Kutschke, A., Ehmann, D. E., Patey, S. A., Crandon, J. L., Gorseth, E., Miller, A. A., McLaughlin, R. E., Blinn, C. M., Chen, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00831-15 · Cited by 79
“The PK/PD index for SMC3176 was reasonably assumed to be time driven (supported by in vitro time-kill results for SMC-3176 [data not shown]), as this has been well-established for various drug classes belonging to the -lactam family (12, 24), and greater emphasis was placed on exploring the potential loss of in vivo e…”
BackgroundResultInfluentialBacterial eradication in the treatment of otitis media
Dagan, R., & Leibovitz, E. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00394-8 · Cited by 82
Microbiology and antimicrobial management of sinusitis
Brook, I. (2005) · The Journal of Laryngology & Otology · doi:10.1258/0022215054020304 · Cited by 82
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
“From a pharmacokinetic and pharmacodynamic standpoint, drugs that exhibit concentration-dependent killing and prolonged postantibiotic effects are most effective when larger dose levels are administered infrequently (Vogelman et al., 1988; Turnidge et al., 1994; Craig, 1998).”
BackgroundBouazza, N., Pestre, V., Jullien, V., Curis, E., Urien, S., Salmon, D., & Tréluyer, J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04292.x · Cited by 81
Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids
Aliabadi, F. S., Ali, B. H., Landoni, M. F., & Lees, P. (2003) · The Veterinary Journal · doi:10.1016/s1090-0233(02)00258-7 · Cited by 80
Hayashi, Y., Lipman, J., Udy, A. A., Ng, M., McWhinney, B. C., Ungerer, J. P. J., Lust, K. M. C., & Roberts, J. A. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.002 · Cited by 81
Kiffer, C. R. V., Sampaio, J. L. M., Sinto, S. I., Oplustil, C. P., Koga, P. C. M., Arruda, A. C., Turner, P. J., & Mendes, C. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.03.003 · Cited by 81
“Furthermore, isolates with MICs above or equal 2 Ag/mL were also chosen because of numerous reports showing the importance of optimizing therapy for infections caused by bacteria with elevated MIC values (Forrest et al., 1993; Craig, 1998; Drusano, 2003; Kuti et al., 2002).”
BackgroundGroll, A. H., & Kolve, H. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1108-6 · Cited by 81
“Understanding these pharmacokinetic-pharmacodynamic relationships provides important knowledge of a drug’s mode of action and can be instrumental in setting susceptibility breakpoints and in guiding optimal dosing regimens [32].”
BackgroundAltered Pharmacokinetics of Ceftazidime in Critically Ill Patients
Gómez, C. M., Cordingly, J. J., & Palazzo, M. G. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1798 · Cited by 81
“The effect of ceftazidime is predominantly time dependent in that it requires continuous antibiotic presence above the MIC to achieve bacterial cell killing (9, 23).”
BackgroundInfluentialHigher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy
Mueller, B. A., Pasko, D. A., & Sowinski, K. M. (2003) · Artificial Organs · doi:10.1046/j.1525-1594.2003.07283.x · Cited by 81
Lutsar, I., Friedland, I. R., Wubbel, L., McCoig, C. C., Jafri, H. S., Ng, W., Ghaffar, F., & McCracken, G. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2650 · Cited by 75
“Experimental studies of pneumonia, peritonitis, and sepsis and clinical trials evaluating fluoroquinolone therapy have shown that AUC/MIC ratios of $100 and Cpeak/MIC ratios of 8 to 10 are almost always associated with satisfactory outcomes (1).”
BackgroundFERRARA, A. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.11.005 · Cited by 81
Kaplan, J. B., Jabbouri, S., & Sadovskaya, I. (2011) · Research in Microbiology · doi:10.1016/j.resmic.2011.03.008 · Cited by 65
“The process of antibioticinduced biofilm formation may have clinical relevance because bacteria are exposed to subMIC concentrations of antibiotics at the beginning and end of a dosing regimen, between doses, or continuously during low-dose therapy (Craig, 1998).”
BackgroundThe role of carbapenems in the treatment of severe nosocomial respiratory tract infections
Joseph, J., & Rodvold, K. A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.4.561 · Cited by 80
“Thus, the goal in dosing carbapenems is to optimize the duration of unbound drug concentrations at or above the MIC [13-15,101] .”
BackgroundInfluentialMouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-06 · Cited by 80
“For beta-lactam antibiotics, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo efficacy has been shown to be the duration that the unbound concentration of an antibiotic remains above the MIC as a percentage of the dosing interval (%fT MIC) (1, 4, 5).”
BackgroundBlassmann, U., Roehr, A. C., Frey, O. R., Vetter‐Kerkhoff, C., Thon, N., Hope, W. W., Briegel, J., & Huge, V. (2016) · Critical Care · doi:10.1186/s13054-016-1523-y · Cited by 80
“The bactericidal activity of meropenem in laboratory animal models requires 40–50 % fT>MIC in plasma [8, 9].”
BackgroundQuinolone Resistance Reversion by Targeting the SOS Response
Recacha, E., Machuca, J., de Alba, P. D., Ramos-Guelfo, M. S., Docobo-Pérez, F., Rodríguez-Beltrán, J., Blázquez, J., Pascual, Á., & Rodríguez-Martínez, J. M. (2017) · mBio · doi:10.1128/mbio.00971-17 · Cited by 80
Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)
Bretonnière, C., Léone, M., Milési, C., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3853-7 · Cited by 80
“For b-lactam antibiotics, the percentage time above the MIC, which varies according to the antibiotic (50–60 % for penicillins, 60–70 % for cephalosporins) [71] and the bacterium, is the best pharmacodynamic predictor of therapeutic efficacy.”
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections
Klugman, K. P. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00400402 · Cited by 80
“These data suggest that if a penicillin drug level exceeding the MIC of a resistant bacterium is required for 40% of the dosing interval, a penicillin dose of 2,000,000 units may be given 4-hourly to treat a highly resistant pneumococcus with an MIC of¡4 mg?mL [15].”
BackgroundLepak, A. J., Zhao, M., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01572-18 · Cited by 79
“The treatment results were analyzed using a sigmoidal maximum effect (Emax) model (12).”
MethodPrinciples of Antibacterial Dosing in Continuous Renal Replacement Therapy
Choi, G. Y. S., Gomersall, C. D., Tian, Q., Joynt, G. M., Li, A. M. M. Y., & Lipman, J. (2010) · Blood Purification · doi:10.1159/000321488 · Cited by 79
“The β-lactams, comprising penicillins, cephalosporins, carbapenems and monobactams, are the classic example of antimicrobials which exhibit time-dependent killing. They have a slow continuous bactericidal effect and killing is most closely related to the duration of time for which the serum concentration exceeds a thr…”
BackgroundRoberts, J. A., Udy, A. A., Jarrett, P., Wallis, S. C., Hope, W. W., Sharma, R., Kirkpatrick, C. M. J., Krüger, P., Roberts, M. S., & Lipman, J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku564 · Cited by 79
Yan, S. S., & Gilbert, J. M. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.010 · Cited by 79
Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
Popejoy, M. W., Miller, B. W., Krishna, G., Hershberger, E., & Chandorkar, G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02151-13 · Cited by 78
Feldman, C. H. (2004) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2004.02.002 · Cited by 78
Antimicrobial Resistance: Factors and Outcomes
Fish, D. N., & Ohlinger, M. J. (2006) · Critical Care Clinics · doi:10.1016/j.ccc.2006.02.006 · Cited by 78
MacVane, S. H., Kuti, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01463-13 · Cited by 78
“Like other -lactams, cephalosporins exhibit time-dependent bactericidal activity where efficacy is correlated with the percentage of the dosing interval during which free drug concentrations remain above the MIC against the organism (% ƒT MIC) (9, 10).”
BackgroundBurdet, C., Grall, N., Linard, M., Bridier‐Nahmias, A., Benhayoun, M., Bourabha, K., Magnan, M., Clermont, O., d’Humières, C., Tenaillon, O., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02244-18 · Cited by 78
“The pharmacokinetic endpoints were the area under the curve of the free plasma concentration over 24 h at steady state (fAUC0 –24,ss), the maximal and trough (minimum) free plasma concentrations (fCmax and fCmin, respectively) at steady state, and the fraction of the time during which the free plasma concentration was…”
BackgroundUse of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141
Mouton, J. W., Schmitt‐Hoffmann, A. H., Shapiro, S., Nashed, N., & Punt, N. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1713-1718.2004 · Cited by 78
“, either area under the concentration-time curve (AUC) and/or peak concentration (both in relation to the MIC) or the time period during which the concentration remains above the MIC (T MIC) (4).”
Background“One-Size-Fits-All”? Optimizing Treatment Duration for Bacterial Infections
Geli, P., Laxminarayan, R., Dunne, M., & Smith, D. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029838 · Cited by 77
“Recent developments in the field of antibiotic pharmacodynamics have led to a better knowledge of the optimal dosage strategies to obtain maximal eradication of the infecting pathogen [34,35].”
BackgroundPharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients
Smith, P. F., Ballow, C. H., Booker, B. M., Forrest, A., & Schentag, J. J. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80103-x · Cited by 77
Gatsing, D., Nkeug, C. F. N., Nji-Nka, B. F., Kuiate, J., & Tchouan, F. M. (2010) · International Journal of Pharmacology · doi:10.3923/ijp.2010.173.182 · Cited by 77
Dose Predictions for Drug Design
Maurer, T. S., Smith, D. A., Beaumont, K. C., & Di, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01365 · Cited by 77
Quinupristin‐Dalfopristin: An Overview
Delgado, G., Neuhauser, M. M., Bearden, D. T., & Danziger, L. H. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.19.1469.34858 · Cited by 77
“The three major pharmacodynamic relationships between antimicrobial pharmacokinetics and bacterial response are the time that drug concentration exceeds MIC (T>MIC), maximum drug concentration versus MIC (Cmax:MIC), and AUC versus MIC (AUC:MIC).(83) Increasing importance is being placed on the correlation of pharmacod…”
BackgroundTreatment of Acute Otitis Media Consensus Recommendations
Hoberman, A., Marchant, C. D., Kaplan, S. L., & Feldman, S. (2002) · Clinical Pediatrics · doi:10.1177/000992280204100602 · Cited by 77
Widespread Use of Fluoroquinolones Versus Emerging Resistance in Pneumococci
Goldstein, E. J. C., & Garabedian‐Ruffalo, S. M. (2002) · Clinical Infectious Diseases · doi:10.1086/344768 · Cited by 77
“cacy correlates slightly better with the AUC:MIC ratio than with the Cma:MIC ratio [28-30].”
BackgroundBurger, R., Guidi, M., Calpini, V., Lamoth, F., Decosterd, L. A., Robatel, C., Buclin, T., Csajka, C., & Marchetti, O. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky370 · Cited by 76
Optimizing Antimicrobial Therapy in Sepsis and Septic Shock
Kumar, A. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.08.004 · Cited by 76
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction
Ahmad, I., Huang, L., Hao, H., Sandérs, P., & Yuan, Z. (2016) · BioMed Research International · doi:10.1155/2016/5465678 · Cited by 76
“Fluoroquinolones and aminoglycosides display this type of killing [37].”
BackgroundResultAntibiotic Lock Technique: Review of the Literature
Bestul, M. B., & VandenBussche, H. L. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.2.211.56947 · Cited by 76
“For antibiotics such as aminoglycosides and fluoroquinolones, known as concentration-dependent killers, optimal and rapid bacterial killing occurs at high concentrations (peak concentrations of at least 8–10 times the minimum inhibitory concentration [MIC] of a targeted organism or, for fluoroquinolones, a 24-hour are…”
BackgroundPharmacokinetic–pharmacodynamic integration of danofloxacin in the calf
Aliabadi, F. S., & Lees, P. (2003) · Research in Veterinary Science · doi:10.1016/s0034-5288(03)00005-5 · Cited by 75
Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis
Sherwin, C. M. T., Svahn, S., van der Linden, A., Broadbent, R. S., Medlicott, N. J., & Reith, D. M. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0637-4 · Cited by 76
“the amikacin peak serum concentration should be higher [maximum serum concentration (Cmax)/minimum inhibitory concentration (MIC) ratio greater than 8:1] in the first to second days of treatment [5–7].”
BackgroundZeller, V., Durand, F., Kitzis, M.-D., Lhotellier, L., Ziza, J.-M., Mamoudy, P., & Desplaces, N. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00389-08 · Cited by 76
The Clinical Significance of Macrolide‐ResistantStreptococcus pneumoniae:It’s All Relative
Nuermberger, E. L., & Bishai, W. R. (2003) · Clinical Infectious Diseases · doi:10.1086/380126 · Cited by 76
“As with b-lactams, the time above MIC appears to correlate best with efficacy for erythromycin and clarithromycin, and optimal efficacy is obtained when the time above MIC is 140%–50% of the dosing interval [22].”
BackgroundAntibiotic stewardship in the ICU: time to shift into overdrive
Mokrani, D., Chommeloux, J., Pineton de Chambrun, M., Hékimian, G., & Luyt, C.-E. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01134-9 · Cited by 56
Cefdinir: A Review of its Use in the Management of Mild-to-Moderate Bacterial Infections
Perry, C. M., & Scott, L. J. (2004) · Drugs · doi:10.2165/00003495-200464130-00004 · Cited by 75
The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance
Selen, A., Dickinson, P. A., Müllertz, A., Crison, J. R., Mistry, H. B., Cruañes, M. T., Martinez, M. N., Lennernäs, H., Wigal, T. L., Swinney, D. C., et al. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24162 · Cited by 75
Frippiat, F., Musuamba, F. T., Seidel, L., Albert, A., Denooz, R., Charlier, C., Bambeke, F. V., Wallemacq, P. E., Descy, J., Lambermont, B. C., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku354 · Cited by 75
Huang, R., Letendre, L. T., BANAV, N., FISCHER, J., & Somerville, B. A. (2009) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2009.01125.x · Cited by 75
“Gamithromycin, as with other macrolides in general, has also been shown to express an extended postantibiotic effect (Merial data on file), which may also support its extended antimicrobial activity (Craig, 1998).”
BackgroundOng, C. T., Tessier, P. R., Li, C., Nightingale, C. H., & Nicolau, D. P. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.06.014 · Cited by 75
Interactions between and host mammalian cells
Braun, L., & Cossart, P. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)90365-4 · Cited by 75
Lodise, T. P., Pypstra, R., Kahn, J. B., Murthy, B. P., Kimko, H. C., Bush, K., Noel, G. J., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01181-06 · Cited by 75
“rounding the mean fT MIC estimate in previous studies (1, 7, 11).”
BackgroundMethodBreakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams
Kerkhoven, D. V., Peetermans, W. E., Verbist, L., & Verhaegen, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg116 · Cited by 75
Rapid and sensitive diagnosis of Toxoplasma gondii infections by PCR
Jalal, S., Nord, C. E., Lappalainen, M., & Evengård, B. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00948.x · Cited by 74
Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions
Wang, Y., Zhu, L., Dong, Z., Xie, S., Chen, X., Lu, M., Wang, X., Li, X., & Zhou, W. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.05.006 · Cited by 75
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01279-12 · Cited by 71
Novelli, A., & Rosi, E. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1380357 · Cited by 74
Young, S. W., Zhang, M., Moore, G. A., PITTO, R. P., Clarke, H. D., & Spangehl, M. J. (2018) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999.0000000000000013 · Cited by 74
“There are limited data on the pharmacodynamics of vancomycin for surgical prophylaxis; however, in treatment models of infection, the pharmacokinetic-pharmacodynamic parameter most predictive of efficacy is the area under the concentration time curve divided by the minimum inhibitory concentration (MIC) [7].”
BackgroundInfluentialPharmacokinetics and Pharmacodynamics of Cephalosporins in Cerebrospinal Fluid
Lutsar, I., & Friedland, I. R. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039050-00003 · Cited by 74
Rodríguez-Hernández, M. J., Cuberos, L., Pichardo, C., Caballero, F. J., Moreno, I., Jiménez-Mejías, M. E., García-Curiel, A., & Pachón, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.479 · Cited by 74
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.